Amgen’s second quarter results reflected broad-based portfolio momentum, with management crediting double-digit growth in key products like Repatha, EVENITY,...
What Happened? Shares of biotech company Amgen (NASDAQ:AMGN) jumped 3.1% in the afternoon session after the company reported strong second-quarter 2026 finan...
Biotech company Amgen (NASDAQ:AMGN) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 9.5% year on year to $10.05 billion...
Amgen (NASDAQ:AMGN) reported second-quarter revenue above $10 billion, up 10% from a year earlier, as growth across several key medicines offset competitive pressure on its bone-health franchise. The company raised its full-year revenue and adjusted earnings outlook while continuing to increase spen
Biotech company Amgen (NASDAQ:AMGN) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 9.5% year on year to $10.05 billion. The company’s fu...
Biotech company Amgen (NASDAQ:AMGN) will be reporting earnings this Tuesday afternoon. Here’s what you need to know. Amgen beat analysts’ revenue expectation...
